Valuation: NovoCure Limited

Market Cap 1.85B 1.62B 1.51B 1.39B 2.61B 179B 2.65B 17.96B 7.03B 87.5B 6.96B 6.81B 302B P/E 2026 *
-10.2x
P/E 2027 * -15.4x
Enterprise Value 1.66B 1.45B 1.35B 1.24B 2.34B 160B 2.37B 16.07B 6.29B 78.29B 6.22B 6.09B 270B EV / Sales 2026 *
2.34x
EV / Sales 2027 * 1.93x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day-4.56%
1 week-4.68%
Current month+0.86%
1 month+12.27%
3 months+17.36%
6 months+7.68%
Current year+18.17%
1 week 15.27
Extreme 15.27
16.52
1 month 13.43
Extreme 13.43
18.08
Current year 9.82
Extreme 9.82
18.92
1 year 9.82
Extreme 9.82
18.92
3 years 9.82
Extreme 9.82
41.51
5 years 9.82
Extreme 9.82
190.83
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Director/Board Member 68 31/05/2018
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

268 0.0002%
30/06/26 Free

Head of Human Resources

1,905 0.0016%
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-4.09%-4.68%-6.26%-60.14% 1.85B
-0.19%+0.02%+36.62%+4.67% 12.48B
+0.26%+12.88%+23.52%+21.52% 6.54B
-3.15%-6.08%+48.77%+21.75% 5.74B
-2.49%+5.84% - - 4.69B
-2.05%+3.07%-29.02%+20.41% 4.47B
+1.31%+3.61%-20.60%-20.58% 4.06B
+0.68%-6.35%-13.24%+205.07% 1.71B
-1.14%+1.00%+58.91%-3.49% 1.57B
-2.07%-5.24%-24.19%-52.99% 1.25B
Average -1.34%+0.85%+8.28%+15.14% 4.44B
Weighted average by Cap. -1.04%+2.35%+17.78%+12.61%

Financials

2026 *2027 *
Net sales 709M 621M 576M 530M 998M 68.39B 1.01B 6.87B 2.69B 33.46B 2.66B 2.6B 116B 796M 698M 648M 595M 1.12B 76.85B 1.14B 7.72B 3.02B 37.6B 2.99B 2.93B 130B
Net income -180M -157M -146M -134M -253M -17.32B -257M -1.74B -681M -8.48B -674M -659M -29.28B -115M -101M -93.94M -86.33M -163M -11.14B -165M -1.12B -438M -5.45B -434M -424M -18.84B
Net Debt -195M -171M -159M -146M -275M -18.82B -279M -1.89B -740M -9.21B -732M -716M -31.81B -317M -278M -258M -237M -447M -30.61B -453M -3.07B -1.2B -14.98B -1.19B -1.16B -51.73B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
22/07/26 $15.28 -4.50% 317,862
21/07/26 $16.00 +0.38% 1,069,311
20/07/26 $15.94 +0.13% 933,512
17/07/26 $15.92 -3.05% 856,319
16/07/26 $16.42 +2.43% 1,117,924
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.00USD
Average target price
24.57USD
Spread / Average Target
+53.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock